These ventures have just started at Accelerate Cambridge. They are at various stages of development, with some having already raised their first seed round.
Avocabo
Avocabo is an online platform that promotes efficient translation services tailored specifically to academic needs. By connecting customers to a core group of University of Cambridge students, we ensure high quality assistance at competitive prices. With a range of over 50 languages and representation in over 100 subject areas, we connect customers to individual students that can provide excellent service with specialised expertise and high language proficiency.
With Avocabo, we want to connect people, especially academics, to a close-knitted community that knows no boundaries for communication.
Baby Safe
The 'Safe Sleep Seat' from Baby Safe is a patented, award-winning reclining child car seat for infants from birth to four years.
Controlled simply and quickly at the touch of a wireless button from the driver's position, it ensures full control of the vehicle at all times, avoiding an increased potential for accidents on today's busy roads. It is the first car seat of its kind to address the problem of the 'head flopped forward' position, which can occur while driving as a child sleeps, avoiding airway restriction and preventing positional asphyxia. With an increased risk of airway restriction, and possible neck injuries to a child left in this position, it is quickly and simply resolved at the touch of a wireless button, without the problem of reclining manually, as with all current car seats on the market today. The manual rotation feature reduces awkward positioning for placing a child in the seat, preventing back problems for parents as the child grows.
Cambridge Biologicals Co
Cambridge Biologicals Co is established by Dr Chiwen Chang in 2018 to commercialise a project developed in the University. It is a first-in-class immunotherapy for inflammatory and angiogenesis related diseases like rheumatoid arthritis and cancers etc. It's in an early stage of fundraising for pre-clinical and clinical trials.
CamDiab
CamDiab is aiming to improve the management of type 1 diabetes and related metabolic disorders. Its product, CamAPS, is an app which connects to a continuous glucose monitor, processes its data and instruct insulin pump to deliver the right amount of insulin reducing the risk of low and high blood glucose levels and reducing the burden of diabetes.
Carryr Technologies
We're on a mission to deliver a rapid and unique experience to fashion e-commerce consumers, making it feel like magic.
We do this by partnering up with city-based fashion retailers so that they can offer their online customers a delivery option that can deliver their orders in as little as an hour and have unwanted items collected without any hassle."
Hyphn Clinical
Clinical trials have been growing increasingly complex for years and despite spiralling costs remain an under-utilised option of health care systems, with only one per cent of the patient population participating in clinical trials and 75 per cent unaware that trials could be an option for treatment. Incorporation of novel technologies to improve the health care system has been incentivised by the government but the uplift hasn't materialised yet and currently, 50 per cent of clinical trials fail to achieve target recruitment and 80 per cent fail to finish on time.
Hyphn Clinical is a digital health platform enabling execution of clinical trials in a smarter, and more efficient way than the traditional "brick-and-mortar" trial conduct model by leveraging three pillars: telemedicine, passive collection of data, and decentralisation of clinical trials. Our product aims to improve execution of clinical trials for investigators while remaining patient-centric by providing a remote access of procedures to patients. Hyphn Clinical is open-source to allow interoperability with other digital products and can be easily installed on any device. Ultimately, Hyphn Clinical is a digital technology enabler. This investigator-focus approach positions Hyphn Clinical with a unique market segment not exploited by the competition with an immediate emphasis on experimental medicine and academic studies.
Kalium Diagnostics
Kalium Diagnostics is developing the world's first blood potassium test suitable for home use. The test will help chronic kidney patients and suffers of rare diseases to manage their health away from hospitals and clinics, improving health and lifestyles and significantly reducing the costs of healthcare provision. Our team combines world-class clinical, scientific and product development expertise.
MAP Innovation
MAP Innovation is a startup company focused on product development primarily within the logistics industry. We are currently developing our own MAP-Ping™ system which is a synergetic product that could also be adapted for other applications.
The system aims to eradicate asset loss and provide customers with an interface that can be utilised to enhance current logistical systems or provide a platform to develop a new one. Our remit was to develop a low cost system that addresses problems associated with similar products, incorporate the latest technology and employ hardware that is reliable, efficient and ideally maintenance free.
Scope
The news we read is heavily biased towards negative clickbait, stories about death and scandal are commonplace and overshadow lots of interesting coverage. Good journalism about current affairs and new technologies is often missed even though it is highly relevant and more beneficial. News providers use negative news to craft big headlines, exploiting human psychology to draw people in. This leads to a disproportionate number of negative stories biasing the news. For example, journalism about how Germany manages to run a budget surplus will never be shown on the BBC homepage.
Scope aggregates news and uses machine learning to automatically detect and reduce the visibility of negative clickbait. The platform, accessible via mobile, tablet and desktop, is delivered through a website and native Android and iOS applications. Scope loads live articles from all major news providers and employees a probabilistic approach to suppress negative clickbait using cutting edge recurrent neural networks. A user enters their favourite news topics and sources, allowing the platform to provide them with a custom-built news feed post filtering; resulting in relevant and previously overshadowed articles being brought to the forefront.
Seedlink
Seedlink are designing a low-cost, easy-to-use chemical swab which tests for pesticide residue on food crops. A large percentage of cocoa exported from West Africa is rejected because of high levels of pesticide residue. Current testing methods are lab-based and far out of reach for smallholder farmers or cooperatives. Seedlink allows testing to take place at the source, so farmers can measure and control their pesticide use. This also gives smallholder farmers the ability to know whether their cocoa passes EU regulations for pesticide use, enabling those farmers to access the lucrative export markets directly.
Spliceor Therapeutics
Spliceor Therapeutics is a research and development biotechnology company in the making based on translational medical research in Professor Andrew Lever's laboratory in the Department of Medicine, University of Cambridge.
Co-founded by Dr Carin Ingemarsdotter and Professor Andrew Lever, the proposed business aims at developing novel curative treatments for HIV and cancer. There is a clear gap in the HIV market for a therapy that can eliminate HIV-infected cells and cure patients from HIV. We are developing HIV therapeutics based on a gene-therapy platform technology and have identified a common mechanism for therapeutic development against many cancers including liver cancer and pancreatic cancer, which addresses major unmet medical needs. These are both very serious diseases that respond poorly or not at all to current treatments. Our mission is to provide gene therapies to HIV-infected patients and cancer patients, to cure patients of HIV and aggressive forms of cancer and save millions of lives.
Trusl Law
Trusl Law is an online legal platform which allows lawyers and their clients to connect and collaborate online. For the clients, the cloud-based offering is a complete end-to-end service which enables legal advice to be personalised, affordable and accessible. For lawyers, it offers a flexible working model that will fall in line with changes to the Solicitors Regulatory Authority guidance which permits freelance work.
Uverify
With fraudulent certificates and degrees being increasingly accessible for purchase online, educational institutions, learners, and employers alike are finding it expensive and time-consuming to verify the authenticity of certificates. Paper-based certificates are also vulnerable to loss or damage. The current systems and record keeping processes are fragmented. Holders of certificates have to deal with multiple institutions, often with different processes, digital systems and agencies to manage and verify them.
Uverify is an instant verification tool that is powered by blockchain technology that addresses these issues. We enable learners to manage and take ownership of their lifetime record of certificates and other professional qualifications. Certificates issued by institutions are digital, instantly verifiable, immutable, and secure. Our digital passport creates a single profile view of the learner’s fragmented credentials. Uverify helps institutions combat fraud and saves them time and money by automating the verification process.
